California Public Employees Retirement System lessened its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) by 8.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 119,466 shares of the biopharmaceutical company’s stock after selling 11,290 shares during the period. California Public Employees Retirement System owned 0.17% of Ultragenyx Pharmaceutical worth $7,127,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently modified their holdings of RARE. IndexIQ Advisors LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the first quarter worth $44,000. Lazard Asset Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 36.6% during the first quarter. Lazard Asset Management LLC now owns 896 shares of the biopharmaceutical company’s stock worth $64,000 after purchasing an additional 240 shares during the period. Harbor Capital Advisors Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical by 25.5% during the second quarter. Harbor Capital Advisors Inc. now owns 2,918 shares of the biopharmaceutical company’s stock worth $174,000 after purchasing an additional 592 shares during the period. Essex Investment Management Co. LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 14.9% during the first quarter. Essex Investment Management Co. LLC now owns 2,682 shares of the biopharmaceutical company’s stock worth $195,000 after purchasing an additional 348 shares during the period. Finally, Echo Street Capital Management LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the first quarter worth $234,000. Institutional investors and hedge funds own 88.27% of the company’s stock.
Ultragenyx Pharmaceutical Trading Down 0.2 %
RARE opened at $34.59 on Thursday. The company has a fifty day moving average price of $39.06 and a two-hundred day moving average price of $47.94. The company has a market cap of $2.42 billion, a P/E ratio of -3.55 and a beta of 1.20. Ultragenyx Pharmaceutical Inc. has a 1-year low of $33.36 and a 1-year high of $88.22.
Analyst Ratings Changes
Insider Transactions at Ultragenyx Pharmaceutical
In other news, CFO Mardi Dier sold 1,629 shares of the business’s stock in a transaction dated Friday, October 14th. The shares were sold at an average price of $40.16, for a total transaction of $65,420.64. Following the completion of the sale, the chief financial officer now directly owns 66,695 shares of the company’s stock, valued at $2,678,471.20. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 6.70% of the stock is currently owned by insiders.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
- Get a free copy of the StockNews.com research report on Ultragenyx Pharmaceutical (RARE)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.